Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Impact of SGLT2 Inhibitors on Cardioprotection in Patients Undergoing Heart Transplantation
Sponsor: Hospital de Messejana
A PHASE2 clinical study on Cardiac Allograft Vasculopathy and Rejection Heart Transplant, this trial is ongoing. The trial is conducted by Hospital de Messejana and has accumulated 4 data snapshots since 2023. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Enrolling By Invitation PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
Dec 2023 — Jun 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Nov 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital de Messejana
- Universidade Federal do Ceara
For direct contact, visit the study record on ClinicalTrials.gov .